Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
Australian dollar (A$) drops below US75 cents: These 4 ASX shares have benefited
⏸️ Investing
Why making big money in the share market is much easier than you think
⏸️ Investing
3 shares I'd love to own at a lower price
⏸️ Investing
The HOLY GRAIL: 10 ASX technology shares with dividends
⏸️ Investing
Are these 3 ASX shares an ideal way to globally diversify your portfolio?
⏸️ Investing
5 Aussie health shares I'm watching in 2017
⏸️ Investing
2 must-have ASX share ideas for a lower Australian dollar ($A) (AUD)
⏸️ Investing
How to pick great dividend shares every month
⏸️ Investing
Revealed: The top 10 performing blue-chip shares of 2017
⏸️ Investing
3 healthcare growth stocks I'd buy with $3,000
⏸️ Investing
3 ASX dividend shares I'd buy for my kids
⏸️ Investing
US Federal Reserve hikes interest rates: What it means for Aussie investors
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
